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Background: Anticoagulation for chronic dialysis patientswith contraindications to heparin administration is challenging.
Current guidelines state that in patientswith increased bleeding risks, strategies that can induce systemic anticoagulation
should be avoided. Heparin-free dialysis using intermittent saline flushes iswidely adopted as themethod of choice for
patients at risk of bleeding, although on-line blood predilutionmay also be used.
A newdialyzer, Evodial (Gambro, Lund, Sweden), is graftedwith unfractionated heparin during themanufacturing process
andmay allow safe and efficient heparin-free hemodialysis sessions. In the present trial, Evodial was compared to standard
carewith either saline flushes or blood predilution.
Methods: TheHepZero study is the first international (seven countries), multicenter (10 centers), randomized, controlled,
open-label, non-inferiority (and if applicable subsequently, superiority) trial with twoparallel groups, comprising 252 end-
stage renal disease patients treated bymaintenance hemodialysis for at least 3months and requiring heparin-free dialysis
treatments. Patientswill be treated during amaximumof three heparin-free dialysis treatmentswith either saline flushes or
blood predilution (control group), or Evodial. The first heparin-free dialysis treatmentwill be considered successful when there
is: no complete occlusion of air traps or dialyzer rendering dialysis impossible; no additional saline flushes to prevent clotting;
no change of dialyzer or blood lines because of clotting; and no premature termination (early rinse-back) because of clotting.
The primary objectives of the study are to determine the effectiveness of the Evodial dialyzer, compared with standard
care in terms of successful treatments during the first heparin-free dialysis. If the non-inferiority of Evodial is demonstrated
then the superiority of Evodial over standard care will be tested. The HepZero study results may have major clinical
implications for patient care.
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Hemodialysis treatment requires anticoagulation, usually
with unfractionated or low molecular weight heparin to
prevent thrombosis of the dialyzer and the extracorporeal
circuit (dialyzer and blood lines or cassette system). In
clinical practice, it is not unusual to perform hemodialysis
for patients with active bleeding or increased bleeding risk
conditions when heparin anticoagulation is contraindi-
cated. Various solutions have been attempted to prevent
clotting of the extracorporeal circuit.
Heparin-free dialysis using intermittent saline flushes
is widely adopted as the method of choice for patients at
risk of bleeding [1,2] and is currently recommended by
the European Best Practice Guidelines in hemodialysis
(2002) [3], although the level of evidence is somewhat
weak since no randomized controlled studies evaluating
this method have been reported to date [4-11]. Heparin-
free treatment with on-line predilution rather than re-
gular saline flushes is also a technique used at some
dialysis units. Saline infusion is far from optimal for sev-
eral reasons, including an increased volume load that
would need to be removed with dialysis and an added
logistic burden on dialysis nurses, owing to the need for
close one-to-one nursing in cases of intermittent boluses
[1]. In addition, this technique is still associated with
clotting risks (15% to 35%, depending on the literature)
which, in addition to blood loss, may reduce the effi-
ciency of a dialysis session that has to be stopped
frequently or prematurely. Regional (heparin adminis-
tration into the arterial line and protamine into the ven-
ous line) or tight heparinization (use of minimal dose of
heparin) is not recommended for patients with active
bleeding or at risk of bleeding [3]. Indeed, although
these methods lower the risk of bleeding compared to
the standard method, there is still a notable risk of
bleeding (5% to 50%) [12].
The use of regional citrate anticoagulation (RCA) is lim-
ited by the need for additional equipment (additional
pumps for citrate and calcium), the potential risk of deteri-
oration of electrolyte and acid–base equilibrium (hypocal-
cemia, hyponatremia) requiring close monitoring of
electrolytes [12], and a need for clotting time evaluation
since the risk of bleeding is reduced but may still occur.
Recently, the feasibility of anticoagulating the extracorpor-
eal circuit during hemodialysis using a simple citrate-
enriched dialysate was evaluated in a pilot (no prespecified
sample size calculation or primary endpoint), monocentric,
prospective, randomized, crossover study of 24 patientswith high risk of bleeding [13]. For anticoagulation of the
extracorporeal circuit, one treatment used the citrate-
enriched dialysate (citrate group), while the other treat-
ment used conventional saline flushing (saline group).
With either method, a heparinized, saline-rinsed polyamide
dialyzer was used and no heparin was administered during
dialysis. Ninety-two per cent (22 out of 24) and 100% of
patients tolerated the procedure well in the citrate group
and saline group, respectively. Eight per cent (two out of
24) of the treatments in each group had to be abandoned
because of clotting in the extracorporeal circuit, while sig-
nificantly less thrombus formation in the venous air traps
was detected in the citrate group [13]. Other alternatives
such as prostacyclin are costly and require close
hemodynamic monitoring [3]. In a pilot (without sample
size calculation or prespecified primary endpoint),
monocentric, randomized, controlled trial, Yixiong et al.
recently compared heparin-free saline flushes with low-
dose argatroban (a direct thrombin inhibitor) in a total of
80 hemodialysis sessions performed in 52 patients with
high risk of bleeding. They observed a three-fold decrease
in major clotting with argatroban (P <0.05), without safety
issues [14].
Another alternative for heparin-free hemodialysis is to
coat heparin on the hemodialyzer hollow fibers [1,12].
Stamatiadis et al. reported the results of 16,954 sessions
performed with patients bleeding or at risk of bleeding
(15,730 retrospectively and 1,224 prospectively col-
lected), with a method combining a priming of two types
of hollow fiber wet dialyzers (ethylene vinyl alcohol and
polyethylene glycol-coated membranes with 1 liter of sa-
line containing 5,000 IU of unfractionated heparin).
After initiation of the treatment, except for hourly rins-
ing with 50 ml normal saline to inspect the circuit (100
ml for a 3-hour session), no other special nursing at-
tendance was applied. Cumulative failure of treatment,
as defined by clotting of the extracorporeal circuit re-
quiring termination of the procedure or replacement of
the clotted part, was not greater than 5% [15].
Gambro (Lund, Sweden) have for several years devel-
oped coated hemodialyzers such as Nephral ST that are
equipped with a membrane, the surface of which is
treated with polyethyleneimine (PEI) allowing extempor-
aneous coating with heparin when the hemodialyzer is
primed with saline solution containing heparin. Several
clinical studies have been performed with Nephral ST to
demonstrate the possibility of decreasing systemic heparin
doses or of even performing hemodialysis treatments
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the AN69 ST membrane in heparin-free dialysis in pa-
tients at risk of bleeding (n = 68) less than 2% massive
clotting were observed (6 out of 331 dialysis sessions) [17].
Evenepoel et al. performed a monocenter, prospective,
randomized trial including 33 hemodialysis patients at
high risk of bleeding, in whom regional anticoagulation
was achieved by means of either AN69 ST (Nephral ST;
11 patients, 31 sessions), RCA-Ca0 (11 patients, 32
sessions) or RCA-Ca3.0 (11 patients, 30 sessions). Clotting
phenomena necessitating premature termination of the
dialysis session were encountered in 39%, 13% and 0%
using AN69 ST, RCA-Ca3.0 and RCA-Ca0, respectively
(P <0.005). The authors concluded to the superiority of cit-
rate regional anticoagulation [19]. In a bicentric, Austrian,
randomized, crossover trial, Kodras et al. treated 10 pa-
tients receiving oral anticoagulants with AN69 ST and FX
100 (a polysulfone membrane) for 1 week (total 30 sessions
of heparin-free dialysis, with only priming of the dialyzer
and no systemic heparinization). Changes of clotting
markers, occurrences of complete thrombosis and Kt/V
were similar with both membranes [20]. More recently, a
prospective, randomized, crossover study examined 10
stable patients during intermittent hemodialysis with: 1.
regular saline flushes of extracorporeal circuit; 2. RCA; and
3. AN69 ST membrane after extracorporeal circuit prim-
ing. All 10 procedures with RCA were successfully com-
pleted after 4 hours, whereas six out of 10 procedures with
saline flushes and five out of 10 procedures with AN69 ST
were terminated prematurely because of clotting (P <0.05).
Due to insufficient statistical power of the negative results,
the number of incomplete procedures did not allow the au-
thors to directly compare saline flushes and AN69 ST [21].
A new dialyzer, Evodial (Gambro), which is an upgrade
of the Nephral ST dialyzer, is grafted with unfractionated
heparin during the manufacturing process. In vitro and
in vivo data requested for CE marking have shown the sta-
bility of heparin grafting. Several clinical studies have been
performed with Evodial [22,23]. A 30% heparinization re-
duction with Evodial dialyzers led to an improvement in
oxidative stress, thereby testifying an effective biocompati-
bility [22]. In a study performed in 45 chronic dialysis pa-
tients, Kessler et al. have shown that the systemic heparin
dose, regardless of heparin type (unfractionated heparin or
low molecular weight heparin), can be reduced by 45% ±
13% without any coagulation issues, which was defined as
very early clotting signs such as quality of rinse-back in
the circuit (dialyzer and blood lines) [18].
The present HepZero study hypothesis is that in patients
requiring heparin-free dialysis, the heparin-free treatment
with Evodial can be easily performed (without saline
flushes or blood predilution) and is at least not inferior
and may be superior to the standard care heparin-free
treatment in terms of clotting, as assessed for the first timeby an international, multicenter, randomized, controlled,
open-label trial with two parallel groups.
Methods/Design
Study design
This clinical study is a prospective, multicenter (10 cen-
ters), international (7 countries), open, controlled, ran-
domized clinical study (Figure 1). Two types of therapies
will be evaluated in parallel.
The control group will receive heparin-free hemodialysis
treatment according to standard care. Since there is no
unique standard heparin-free treatment, the control group
will receive the usual procedure in place at each study site
(saline flushes or predilution) with guidelines aimed at
standardizing practices within the control group. The
standard care can be either saline flushes during dialysis
treatment (100 ml to 300 ml per flush every 30 minutes,
as stated in the European Best Practice Guidelines (2000)
[3]) or predilution (on-line or bags, with a predilution rate
between 1 l/h and 2 l/h; high-volume hemodiafiltration is
not allowed).
The study device group will receive heparin-free
hemodialysis treatment with Evodial. To allow the com-
parison, a dialyzer with roughly the same surface area as
Evodial 1.6 (1.65 m2) will be used in the study group.
Consecutive patients will be screened by the investiga-
tors and, when eligible, will be enrolled in the study and
treated during a maximum of three consecutive heparin-
free dialysis treatments, without any switch allowed be-
tween arms.
Primary objectives
The primary objectives of the study are to determine the
effectiveness of the Evodial dialyzer, compared with
standard care in terms of successful treatments during
the first heparin-free dialysis. If the non-inferiority of
Evodial is demonstrated then the superiority of Evodial
over standard care will be tested.
Secondary objectives
The secondary objectives are: to compare the success rate
during the second and third consecutive heparin-free dialy-
sis treatment with Evodial to standard care; to compare
clotting grades in air traps during all treatments with
Evodial versus standard care; to assess the efficacy of
heparin-free dialysis treatment with Evodial versus standard
care; to assess the ease of use of heparin-free dialysis treat-
ment with Evodial; and to follow-up the safety of heparin-
free dialysis treatment with Evodial versus standard care.
Study population
The patients to be included in this clinical study are
end-stage renal disease patients treated by maintenance
hemodialysis for at least 3 months and requiring heparin-
Figure 1 Study flow-chart.
Rossignol et al. Trials 2013, 14:163 Page 4 of 9
http://www.trialsjournal.com/content/14/1/163free dialysis treatments. Reasons for heparin-free dialysis
prescription will be recorded and may include: gastrointes-
tinal hemorrhage; invasive procedure: pre-, post-procedure;
perioperative: pre- or post-surgery; cerebral hemorrhage:
type and date; other bleeding risk; other reason not related
to bleeding risk; cholesterol emboli; diabetic retinopathy;
and other reason.
Bleeding risk will be graded according to the Lohr and
Schwab definition [24]: very high risk, active bleeding at
time of dialysis; high risk, active bleeding stopped for less
than 3 days or surgery or trauma within the previous 3
days; moderate risk, active bleeding stopped for more than
3 days but less than 7 days, surgery or trauma within the
previous 3 to 7 days, or uremic pericarditis or pleuritis;
and low risk, greater than 7 days after active bleeding, sur-
gery or trauma.
These patients shall meet the following inclusion and
exclusion criteria defined for this study. Inclusion cri-
teria are the following: patients requiring heparin-free
dialysis treatments as per nephrologists’ prescription;
chronic end-stage renal disease patients treated by main-
tenance hemodialysis for at least 3 months; patients with
a well-functioning blood access that can allow a blood
flow of at least 250 ml/min; patients aged 18 years or
older;written consent to participate in the study (in-
formed consent).
Patients that have already been treated with heparin-free
hemodialysis can be included into the study. The first
treatment is defined as the first treatment evaluated when
the patient is enrolled in the study. Patients with a catheterlocked by heparin can be included in the study, although
particular attention must be paid to the removal of hep-
arin and the rinsing of the catheter prior to starting the
hemodialysis treatment.
Exclusion criteria are the following: patients in inten-
sive care unit settings; acute kidney injury patients; pa-
tients dialyzed in self-care, satellite hemodialysis units;
patients treated in single needle mode; known heparin
contraindication (heparin-induced thrombocytopenia
type II); patients requiring blood and other labile blood
products (for example fresh frozen plasma, platelets)
transfusion during hemodialysis treatment; patients re-
ceiving oral anticoagulants (including anti-vitamin K);
patients receiving a combination of anti-platelet agents;
patients treated with unfractionated or low molecular
weight heparin in addition to the dialysis treatment to pre-
vent deep vein thrombosis; pregnant/planning pregnancy
and lactating women during the study period; legally-
protected adult patients; patients not affiliated with a
health insurance system (beneficiary or dependent); par-
ticipation in other interventional studies during the study
period; and patients that have already been included in
this study.
Patients will be considered enrolled in the study when
the informed consent has been signed. Time zero is
when the randomization is done. Withdrawn patients
will be replaced only if the patient has been randomized
and no dialysis treatment could have been performed or
in case of an improper second enrolment of the same
patient (the second one being not considered).
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Primary endpoints
In order to evaluate the rate of successful treatments,
clotting in the air traps will be scored using a semi-
quantitative scale (Figure 2) [13,14,19,20,25,26]: grade 1,
no detectable clotting; grade 2, minimal clot formation
(presence of fibrinous ring); grade 3, clot formation (up
to 5 cm) but dialysis still possible; and grade 4, complete
occlusion of air traps or dialyzer rendering dialysis
impossible.
The first heparin-free dialysis treatment will be consid-
ered successful when there is: no complete occlusion of
air traps or dialyzer rendering dialysis impossible (grade
4); no additional saline flushes to prevent clotting; no
change of dialyzer or blood lines because of clotting; and
no premature termination (early rinse-back) because of
clotting.
This evaluation (clotting scoring) will be performed
hourly by two independent observers. Depending on theFigure 2 Visual clotting scale.organization at each study site, the evaluation can be
performed by two nurses (the nurse in charge of the pa-
tient and a second nurse not in charge of the patient) or
by the nurse in charge of the patient and a co-investigator.
In case of discordance between the two observers or in
the eventuality of premature session termination (grade
4), the final decision will be made by a third authorized
and trained person (the principal investigator or registered
co-investigators).
At each site and prior to the enrolment of patients, an
organization will be implemented, and the investigator
and all those involved in the study will be trained and cer-
tified with regard to scoring.Secondary endpoints
The follow-up of the clotting during the first heparin-free
dialysis treatment will be performed at each hour through-
out the dialysis session; clotting in the air traps will be
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scribed above.
The evaluation of the success rate during the second
and the third consecutive heparin-free dialysis treat-
ments will be as for the first heparin-free dialysis treat-
ment. Treatments will be considered successful when
there is: no complete occlusion of air traps or dialyzer
rendering dialysis impossible (grade 4); no additional sa-
line flushes to prevent clotting; no change of dialyzer or
blood lines because of clotting; and no premature stop-
page (early rinse-back) because of clotting. This eva-
luation will be performed by two independent observers
as described in the aforementioned primary endpoint
section.
Follow-up of the clotting during the second and the
third consecutive heparin-free dialysis treatment will be
performed at every hour; clotting in the air traps will be
assessed using the same semi-quantitative scale as de-
scribed above.
To undertake hemodialysis session efficacy assessment,
the ultrafiltration (UF) achieved, weight loss, serum cre-
atinine and urea reduction rates, as well as electrolytes
changes will be documented during all dialysis sessions.
To measure ease of use, the frequency and remaining
volume of saline flushes will be documented. The occur-
rence of adverse events and serious adverse events dur-
ing the study will be collected.Ethics
Inclusion in the study was initiated in 2011 after approval
of the appropriate ethics committee (Comité de Protection
des Personnes, Sud Est III Lyon, France; Comité Ético de
Investigación Clínica, Vall d’Hebron Hospital, Barcelona,
Spain; Comité Ético de Investigación Clínica, Germans
Trias i Pujol Hospital, Barcelona, Spain; National Research
Ethics Service, Yorkshire and the Humber – Sheffield, UK;
Comité d’éthique, Université Libre de Bruxelles, Hôpital
Erasme, Brussels, Belgium; Comité d’éthique de la
recherche Centre hospitalier universitaire, Dr-Georges-
L-Dumont, Moncton, Canada; Medisch Ethische
Toetsingsingscommissie, Universitair Medisch Cen-
trum Groningen, Groningen, the Netherlands; and
the Independent Bioethic Committee for Scientific
Research, Gdańsk Medical University, Gdańsk, Poland)
and competent authorities where applicable. The study
protocol was recorded prior to any enrolment at
ClinicalTrials.gov: NCT01318486.Statistics
Allocation of treatments will be performed using a cen-
tralized, on-line randomization system. Patients will be
assigned to treatment groups using block randomization
stratified on centers.Justification of sample size
The main criterion of efficacy is the success rate in the
Evodial group (test) compared to standard care (on-line
predilution or saline flushes). After completion of the
study, the analysis will follow a two-step procedure and
the probability that the efficiency of Evodial is inferior to
that of the standard care will be tested first. If that prob-
ability is rejected at the 5% significance level, that is if
non-inferiority is demonstrated, then superiority will be
tested. The probability of simultaneously falsely accepting
inferiority and superiority being mutually exclusive, no ad-
justment of alpha error rate will be requested. According
to the results, the conclusion will be: Evodial is inferior,
not inferior but not superior, or superior to the standard
care.
According to the data published on heparin-free treat-
ment (with saline flushes or on-line predilution), the suc-
cess rate of hemodialysis ranges from 65% to 85%. Recent
works presented at the French Society of Nephrology,
September 2010, meeting in Brussels, showed a 15% to 20%
improvement of these success rates using preheparinated
dialysis membranes (HeprAN, Gambro, or AN69 ST)
[27,28]. The non-inferiority as well as superiority margins
will be set to the same value of 15%. In the hypothesis of a
65% success rate (the most patient-consuming) in the con-
trol arm, a sample size of 126 patients per arm (252 for
the entire sample) will provide the trial with 80% power to
first conclude to non-inferiority then to superiority, with a
one-tailed 5% error rate. Assuming an equal inclusion rate
in all centers, 26 patients will be enrolled in each of the 10
centers, with 13 patients in each arm. Withdrawn patients
will be replaced only if the patient has been randomized
and no dialysis treatment could have been performed.
Efficacy analysis
Baseline comparability
The baseline comparability of groups will be checked,
using the center as an adjustment factor. Should one or
more factors show significant imbalance, the steering com-
mittee will assess the impact of the possible confounding
factor(s) on further analyses and decide whether it is neces-
sary to take it into account during the blind review of data.
Adjustment will be performed using logistic regression.
Primary objective
The success of hemodialysis is defined as the proportion
of first treatment achieved without prematurely halting
dialysis or having to change blood lines or dialyzer, owing
to clotting or any additional saline flush because of clot-
ting. The 95% one-tailed confidence interval of the test-
reference difference will be constructed using the Wilson
method [29], and non-inferiority then superiority accepted
if its lower boundary is found to be greater than −15%
then +15%. The consistency of responses across centers
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geneity of odds ratios or logistic regression as appropriate.
Though unexpected, the impact of maneuvers in the con-
trol arm (predilution or saline flushes, centre-specific) will
be tested and, if necessary, taken into account as a nested
factor in the analyses.
Secondary objectives
The treatment groups will be compared for efficacy
(success rates in second and third treatments, achieve-
ment of the planned weight loss and UF volume) and
safety using the Mantel-Haenszel test stratified on center
or logistic regression as appropriate.
Patient populations
The full analysis set will consist of all patients who re-
ceived at least one treatment and had one efficacy assess-
ment. Since the primary criterion is the success of the first
treatment, no dropout is expected, and intention-to-treat
and per-protocol populations will be identical except in
case of deviations (for example not allowed medication or
inappropriate hemodialysis modality with regard to the
randomization arm).
Study organization (in the Additional file 1 the steering
committee, DSMB and HepZero investigators are listed)
Steering committee
In conjunction with the sponsor, a steering committee will
oversee the trial. The steering committee is the main pol-
icy and decision-making committee of the study and has
final responsibility for scientific conduct. The specific
tasks of the steering committee are to: approve by signing
the study protocol and protocol amendments; provide rec-
ommendations to solve problems in cooperation with the
clinical study manager; and approve study reports and ar-
ticles for publications (including abstracts) and presenta-
tion of clinical data of any investigator.
The steering committee is comprised of three investiga-
tors participating in this study, one methodologist and
nephrologist (PR) and two representatives from the study
sponsor, Gambro.
An independent Data and Safety Monitoring Board
(DSMB) will monitor the safety and efficacy of the trial
and periodically assess whether the trial should continue
to the planned termination. Based on the safety data, the
DSMB may recommend modifications to the protocol (for
example amendments, termination of the study) and,
when needed, the DSMB will decide on stopping rules.
The DSMB will consist of three members. No member of
the DSMB will act as an investigator for the study. Mem-
bers of this board are not affiliated with Gambro, the prin-
cipal investigators or the clinical investigation. They will
declare any conflicts of interest if such should arise.
The DSMB will report to the chairman of the steeringcommittee, who in turn is responsible for implementing a
decision to terminate the trial prematurely if deemed
necessary.
Discussion
Anticoagulation for chronic dialysis patients with contrain-
dications to heparin administration is challenging. The
regimens used as alternatives, for example anticoagulation-
free dialysis, regional heparinization with protamine, direct
thrombin inhibitors, prostacyclin or RCA, encounter con-
siderable limitations. Current guidelines state that in pa-
tients with increased bleeding risks, strategies that can
induce systemic anticoagulation should be avoided. Treat-
ment strategies that avoid this include no use of anticoagu-
lants with regular flushing or RCA [3]. To date, the use of
RCA is restricted to specialized units, since its application
is cumbersome [26], because it usually requires additional
pumps for citrate and calcium infusions, which are not
provided by standard dialysis machines, as well as the need
for careful monitoring of electrolytes. These issues not only
increase the complexity of the RCA procedure but also the
likelihood of complications, the most dangerous being sys-
temic hypocalcemia, since it can cause life-threatening ar-
rhythmias [30]. Therefore, heparin-free dialysis using saline
infusion is currently de facto considered as the gold stand-
ard in patients with high risk of bleeding [1,2] and serves
as the control intervention in the present trial. For obvious
logistical and technical reasons, the study is conducted as
open-label and the primary endpoint could not be assessed
blindly. Indeed, neither the predilution process nor the sa-
line flushes can be masked and the dialyzers can easily be
differentiated by the nursing staff (different housings, dif-
ferent membrane colors and transparency), since they must
be carefully examined during the dialysis treatment and
they cannot be completely covered by a label aimed at
preventing any differentiation between the two groups. In
order to minimize potential bias due to the open-label
design, it was decided to have the study primary endpoint:
1. evaluated by the most widespread semi-quantitative
clotting scale used in research [13,14,19,20,25,26]; 2. inde-
pendently rated by two observers; in case of discordance
between the two observers or in case of premature session
stoppage (grade 4), the final adjudication must be made by
a third authorized and trained person (the principal investi-
gator or registered co-investigators); and 3. training and
certification of nurses and investigators with regard to
grading.
Several protocols of heparin-free dialysis are currently
being used in routine practice, which may include saline
flushes delivered at frequent intervals, requiring close
monitoring by dialysis staff, or predilution, where a con-
tinuous infusion of saline is run to the dialyzer; the former
procedure being the most commonly used. Taking into ac-
count this heterogeneity and in order to increase the
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allow both types of saline infusions, which reflect real-life
situations; however, accompanied with guidelines relative
to the volume and output of saline infusion, in order to
minimize the heterogeneity within the control group. To
the best of our knowledge, the HepZero study is the first
international, multicenter, randomized, controlled study
aimed at comparing two techniques of heparin-free dialy-
sis, including its gold standard, in two parallel groups, in
an open-label design. It is sufficiently powered to first
evaluate the non-inferiority of Evodial (which may allow a
decrease in dialysis staff workload during heparin-free
dialysis sessions) then its potential superiority versus the
standard care of saline infusions, and may therefore have
major clinical implications for patient care.
Trial status
Trial status at the time of submission the 15th January
2013: 245 patients recruited.
Additional file
Additional file 1: Appendix (supplementary material).
Abbreviations
DSMB: Data and Safety Monitoring Board; PEI: Polyethyleneimine;
RCA: Regional citrate anticoagulation; UF: Ultrafiltration.
Competing interests
The authors declare that they have no competing interests relevant to the
present manuscript, besides the disclosures presented below.
Authors’ contributions
The authors are HepZero steering committee members as well as the study
statistician (RF). They conceived of the study, participated in its design and
coordination, and helped to draft the manuscript. All authors read and
approved the final manuscript.
Acknowledgments
The HepZero study is sponsored by Gambro. The authors thank Mr Pierre
Pothier for editing the manuscript.
Disclosures
Steering committee members and DSMB members received honoraria from
Gambro for their scientific advice and expertise. FM and NL are Gambro staff
members. The results presented in this paper have not been published
previously in whole or part.
Author details
1INSERM, Centre d’Investigations Cliniques 9501, Institut lorrain du Cœur et
des Vaisseaux Louis Mathieu, 4 Rue du Morvan, 54500 Vandoeuvre lès Nancy,
France. 2Université de Lorraine, Lorraine 54500 Vandoeuvre lès Nancy, France.
3CHU de Nancy, Nancy 54500 Vandoeuvre lès Nancy, France. 4INSERM U1116,
54500 Vandoeuvre lès Nancy, France. 5Association Lorraine pour le
Traitement de l’Insuffisance Rénale, 54500 Vandoeuvre lès Nancy, France.
6Centre hospitalier universitaire Dr-Georges-L-Dumont, Moncton NB E1C 2Z3
Canada. 7Nephrology Department, Dialysis unit, University Hospiital Vall
d'Hebron, Paseo Vall d’Hebron 119-129, 08035 Barcelona, Spain.
8Autonomous University of Barcelona, Barcelona, Spain. 9Gambro-Hospal,
69881 Meyzieu, France. 10Service de Néphrologie, Centre Hospitalier Lyon-
Sud, 69495 Pierre-Bénite, France. 11Université Lyon 1, 69100 Villeurbanne,
France. 12Inserm U1060-Institut CarMeN, 8 Avenue Rockefeller, 69373 Lyon,France. 13Association pour l’Utilisation du Rein artificiel à Lyon (AURAL), 124
Rue Villon, 69008 Lyon, France.
Received: 14 January 2013 Accepted: 1 May 2013
Published: 1 June 2013
References
1. Mujais SK, Chimeh H: Heparin free hemodialysis using heparin coated
hemophan. ASAIO J 1996, 42:M538–M541.
2. McGill RL, Blas A, Bialkin S, Sandroni SE, Marcus RJ: Clinical consequences
of heparin-free hemodialysis. Hemodial Int 2005, 9:393–398.
3. European Best Practice Guidelines Expert Group on Hemodialysis, European
Renal Association Guideline Practice Guideline: Section v. Chronic intermittent
haemodialysis and prevention of clotting in the extracorporal system.
Nephrol Dial Transplant 2002, 17(Suppl 7):63–71.
4. Casati S, Graziani G, Ponticelli C: Hemodialysis without anticoagulants in
patients with high bleeding risk. Int J Artif Organs 1982, 5:233–236.
5. Hathiwala S: Dialysis without anticoagulation. Int J Artif Organs 1983,
6:64–66.
6. Casati S, Moia M, Graziani G, Cantaluppi A, Citterio A, Mannucci PM, Ponticelli C:
Hemodialysis without anticoagulants: Efficiency and hemostatic aspects.
Clin Nephrol 1984, 21:102–105.
7. Agresti J, Conroy JD, Olshan A, Conroy JF, Schwartz A, Brodsky I, Krevolin L,
Chinitz J: Heparin-free hemodialysis with cuprophan hollow fiber dialyzers
by a frequent saline flush, high blood flow technique. Trans Am Soc Artif
Intern Organs 1985, 31:590–594.
8. Sanders PW, Taylor H, Curtis JJ: Hemodialysis without anticoagulation.
Am J Kidney Dis 1985, 5:32–35.
9. Caruana RJ, Raja RM, Bush JV, Kramer MS, Goldstein SJ: Heparin free
dialysis: Comparative data and results in high risk patients. Kidney Int
1987, 31:1351–1355.
10. Preuschof L, Keller F, Seemann J, Offermann G: Heparin-free hemodialysis
with prophylactic change of dialyser and blood lines. Int J Artif Organs
1988, 11:255–258.
11. Keller F, Seemann J, Preuschof L, Offermann G: Risk factors of system
clotting in heparin-free haemodialysis. Nephrol Dial Transplant 1990,
5:802–807.
12. Kim YG: Anticoagulation during haemodialysis in patients at high-risk of
bleeding. Nephrology (Carlton) 2003, 8(Suppl):S23–S27.
13. Cheng YL, Yu AW, Tsang KY, Shah DH, Kjellstrand CM, Wong SM, Lau WY, Hau
LM, Ing TS: Anticoagulation during haemodialysis using a citrate-enriched
dialysate: a feasibility study. Nephrol Dial Transplant 2011, 26:641–646.
14. Yixiong Z, Jianping N, Yanchao L, Siyuan D: Low dose of argatroban saline
flushes anticoagulation in hemodialysis patients with high risk of
bleeding. Clin Appl Thromb Hemost 2010, 16:440–445.
15. Stamatiadis DN, Helioti H, Mansour M, Pappas M, Bokos JG, Stathakis CP:
Hemodialysis for patients bleeding or at risk for bleeding, can be simple,
safe and efficient. Clin Nephrol 2004, 62:29–34.
16. Lavaud S, Canivet E, Wuillai A, Maheut H, Randoux C, Bonnet JM, Renaux JL,
Chanard J: Optimal anticoagulation strategy in haemodialysis with
heparin-coated polyacrylonitrile membrane. Nephrol Dial Transplant 2003,
18:2097–2104.
17. Lavaud S, Paris B, Maheut H, Randoux C, Renaux JL, Rieu P, Chanard J:
Assessment of the heparin-binding an69 st hemodialysis membrane: Ii.
Clinical studies without heparin administration. ASAIO J 2005, 51:348–351.
18. Kessler M, Gangemi C, Gutierrez Martones A, Lacombe JL, Krier-Coudert MJ,
Galland R, Kielstein J, Moureau F, Loughraieb N: Heparin-grafted dialysis
membrane allows minimal systemic anticoagulation in regular
hemodialysis patients: A prospective proof-of-concept study. Hemodial
Int 2013, 17:282–293.
19. Evenepoel P, Dejagere T, Verhamme P, Claes K, Kuypers D, Bammens B,
Vanrenterghem Y: Heparin-coated polyacrylonitrile membrane versus
regional citrate anticoagulation: a prospective randomized study of 2
anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis
2007, 49:642–649.
20. Kodras K, Benesch T, Neumann I, Haas M: Comparison of two dialysers (an69st
vs. Fx100) for heparin-free dialysis in patients with oral anticoagulation.
Blood Purif 2008, 26:226–230.
21. Richtrova P, Rulcova K, Mares J, Reischig T: Evaluation of three different
methods to prevent dialyzer clotting without causing systemic
anticoagulation effect. Artif Organs 2011, 35:83–88.
Rossignol et al. Trials 2013, 14:163 Page 9 of 9
http://www.trialsjournal.com/content/14/1/16322. Morena M, Jaussent I, Chalabi L, Bargnoux AS, Dupuy AM, Badiou S, Rakic C,
Thomas M, Canaud B, Cristol JP: Biocompatibility of heparin-grafted
hemodialysis membranes: Impact on monocyte chemoattractant
protein-1 circulating level and oxidative status. Hemodial Int 2010,
14:403–410.
23. Sanchez-Canel JJ, Pons-Prades R, Salvetti ML, Seores A, Vazquez M, Perez-
Alba A, Tamarit E, Calvo-Gordo C, Villatoro J: Evaluation of coagulation and
anti-xa factor when using a heparin-coated an69st(r) dialyser. Nefrologia
2012, 32:605–612.
24. Lohr JW, Schwab SJ: Minimizing hemorrhagic complications in dialysis
patients. J Am Soc Nephrol 1991, 2:961–975.
25. Ziai F, Benesch T, Kodras K, Neumann I, Dimopoulos-Xicki L, Haas M:
The effect of oral anticoagulation on clotting during hemodialysis. Kidney
Int 2005, 68:862–866.
26. Wright S, Steinwandel U, Ferrari P: Citrate anticoagulation using ACD
solution A during long-term haemodialysis. Nephrology (Carlton) 2011,
16:396–402.
27. Bertrand D, Hanoy M, Le Roy F, Godin M: Comparaison de deux modalités
de dialyse sans héparine à la technique de reference des rincages:
Abstract presented at the sfd annual congress. Nephrol Ther 2010,
6:281–299.
28. Guéry B, Servais A, Harrami E, Bererhi L, Zins B, Lesavre P, Touam M,
Alberti C, Joly D: Hémodialyse sans héparinisation systemique:
Comparaison de trois protocoles: Abstract presented at sfd annual
congress. Nephrol Ther 2010, 6:281–299.
29. Newcombe RG: Estimating the difference between differences:
Measurement of additive scale interaction for proportions. Stat Med 2001,
20:2885–2893.
30. Kozik-Jaromin J, Nier V, Heemann U, Kreymann B, Bohler J: Citrate
pharmacokinetics and calcium levels during high-flux dialysis with
regional citrate anticoagulation. Nephrol Dial Transplant 2009,
24:2244–2251.
doi:10.1186/1745-6215-14-163
Cite this article as: Rossignol et al.: Rationale and design of the HepZero
study: a prospective, multicenter, international, open, randomized,
controlled clinical study with parallel groups comparing heparin-free
dialysis with heparin-coated dialysis membrane (Evodial) versus
standard care: study protocol for a randomized controlled trial. Trials
2013 14:163.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
